等待开盘 11-11 09:30:00 美东时间
-0.160
-7.92%
Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, compared to $27.6 million for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the
11-07 05:57
Rani Therapeutics announced a $1.085 billion collaboration with Chugai Pharmaceutical to develop oral therapies using its RaniPill® platform. The company also completed a $60.3 million private placement led by Samsara BioCapital and appointed Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. With enhanced cash runway into 2028, Rani plans to initiate a Phase 1 clinical trial for its obesity treatment RT-114 by year-end.
11-06 21:30
“大空头”挑战AI泡沫,同时买入辉瑞、哈里伯顿看涨期权;英伟达、Palantir期权多空分歧巨大;AMD绩后大跌近5%,期权成交翻倍>>
11-05 17:05
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
11-01 01:06
SAN JOSE, Calif., Oct. 30, 2025 – Rani Therapeutics Holding, Inc. announced that it will present preclinical data on its RaniPill® capsule at ObesityWeek® 2025 on November 4-7, 2025, in Atlanta, Georgia. The presentation titled "Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss" will be part of a poster session on November 6, 2025, from 2:30 pm – 3:30 pm E.T., featuring Rani's oral delivery platfo...
10-30 12:00
Insiders have been trading these 5 stocks: (($EPAM)), (($WAB)), (($KALA)), (($R...
10-25 21:01
Rani Therapeutics announced the appointment of Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors, while Andrew Farquharson and Maulik Nanavaty have stepped down. The company also closed a private placement raising approximately $60.3 million, led by Samsara BioCapital, with participation from Anomaly Ventures, RA Capital Management, and others. Rani focuses on oral delivery of biologics and drugs, developing the RaniPill® capsul...
10-23 20:05
散户追捧+业务规模扩大!BYND大涨146.3%,近三交易日涨约6倍;生物技术股RANI涨26.7%,与中外制药达成重大合作协议>>
10-22 14:01
今日重点评级关注:摩根大通:维持Cogent Biosciences"超配"评级,目标价从30美元升至44美元;Piper Sandler:维持Vital Energy"中性"评级,目标价从16美元升至30美元
10-22 10:10
广船国际技术暴涨逾155%!AI芯片性能媲美主流图形处理器;“人造肉”公司BYND大涨超127%,将近11.5亿美元零息可转换债券置换成新的资产组合>>
10-21 14:37